Dr. Leland C. Clark Jr. This is Me

 View all 11 references Web References

1. 1. www.sec.gov

   www.sec.gov/Archives/edgar/dat - [Cached]

   Published on: 7/18/2003   Last Visited: 7/22/2003

   No assurance may be given that FDA approval will be granted.   SYNTHETIC BLOOD INTERNATIONAL INC’s technology is based on research done by Dr. Leland C. Clark, Jr., a widely recognized, pioneering inventor and scientist. Dr. Clark, who is credited with developing the first blood oxygenator for open heart surgery as well as biomedical applications for perfluorocarbons and biosensors, was SYNTHETIC BLOOD INTERNATIONAL INC’s Vice President of R&D until 1998.   SYNTHETIC BLOOD INTERNATIONAL INC began conducting business in its current form in September 1990, shortly thereafter changed its name to Synthetic Blood International, Inc., and revised its business purpose to developing a line of blood substitutes.   MARKET     TECHNOLOGY   SYNTHETIC BLOOD INTERNATIONAL INC’s principal technologies, biomedical uses for perfluorocarbons and substrate analysis with biosensors, were conceptualized and advanced by Dr. Leland C. Clark, Jr. While his pioneering discoveries in these two areas spawned decades of research worldwide, Dr. Clark has been one of the most prolific contributors and has remained at the forefront of scientific advances in these areas, leading to SYNTHETIC BLOOD INTERNATIONAL INC’s patented perfluoroc rbon and biosensor technology platforms.   Perfluorocarbons in Biomedicine   Following an experiment showing that a mouse could live and breathe submerged in oxygen-saturated silicone oil, Dr. Clark showed in 1965 that animals could be kept alive submerged for several hours in oxygen-saturated perfluorocarbon liquids. These experiments suggested that perfluorocarbons might be useful in medicine, principally in liquid breathing and in blood substitutes, and in 1975, Dr. Clark was issued the first patent for an oxygen-carrying, perfluorocarbon-based blood substitute. Although the technology described in this patent was used by the Green Cross Corporation in Japan to develop and obtain FDA approval for Fluosol DA, Dr. Clark recognized that further research would be necessary before safe, effective perfluorocarbons could be identified. Since that time, a principal focus of his and SBI’s subsequent research has been the identification of optimal properties for biomedical perfluorocarbons, and the screening of numerous compounds.   Biosensor Substrate Analysis   In the mid-1950’s, Dr. Clark developed the first oxygen electrode. Ten years later, he applied for a patent describing enzyme-based biosensors that could accurately measure glucose, lactate, and other substrates.
   ...
   SBI has also exclusively licensed three fundamental biosensor patents issued to Dr. Clark that have been assigned to Children’s Hospital in Cincinnati.   For all U.S. patents and applications, SYNTHETIC BLOOD INTERNATIONAL INC also submits applications and pursues patents in Europe, Canada, Japan and Australia.

2. 2. mip: Archive

   www.mitophysiology.org/index.p - [Cached]

   Published on: 12/23/2005   Last Visited: 11/21/2007

   Dr. Leland Clark - inventor of the "Clark Oxygen Sensor" (1918-2005)

3. 3. Headlines/Breaking News from Dayton Business Journal - bizjournals.com

   dayton.bizjournals.com/site_ma - [Cached]

   Published on: 10/11/2005   Last Visited: 10/11/2005

   Dr. Leland Clark, former vice president of research and development at Synthetic Blood and inventor of the Clark oxygen and glucose biosensors, is the author of the patent application.